Aphria (TSX:APH) has completed its largest export of cannabis oil to date through a shipment to Australia’s Medlab Clinical (ASX:MDC), it announced on Thursday (July 26).

The record-breaking shipment comes as part of a prior agreement between the two companies, through which Aphria produces and supplies cannabis extracts. Medlab then uses the extracts in human trials to test pain management in oncology patients. For these clinical trials, Aphria provided both a high-CBD cannabis oil and a high-THC oil, both specifically designed for Medlab.


“Aphria is proud to support Medlab’s important and vital clinical research on the use of medical cannabis as an alternative treatment for pain management,” Vic Neufeld, Aphria CEO said in the statement.

“Medlab was our very first international partner, and as Aphria expands its operations around the globe, we will continue support the advancement of medical cannabis research through these valuable partnerships.”

Upon arrival at Medlab, the products shipped by Aphria are combined with the company’s medicine delivery system NanoCelle. Medlab is working towards finding an effective pain therapy method that targets advanced cancer pains through cannabis as opposed to opioids.

“Trial design, implementation and management is critical to developing a new, accepted drug – the work we are undertaking is to expand the medical toolkit especially with regards to current usage of opioids in patients with intractable pain,” Dr. Sean Hall, Medlab CEO said in a statement.

Aphria also has a shipment agreement in place with fellow Australian partner Althea Company, where Aphria provides cannabis oil and dried flower product for Australia’s medical cannabis market. The first shipment happened in late April of this year.

Shares of Aphria increased 0.09 percent on Thursday to close the trading session at C$10.45. Analysis consensus on TipRanks currently ranks the company as a “Strong Buy” with all three analysts giving the company a “Buy” rating. Aphria has an average price target of C$23.58, with a high estimate of C$26.25 and a low of C$20.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less